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Abstract
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related deaths in the United States. The purpose of this study was to evaluate the
gene expression differences in different stages of CRC. Gene expression data on 433 CRC
patient samples were obtained from The Cancer Genome Atlas (TCGA). Gene expression
differences were evaluated across CRC stages using linear regression. Genes with
p0.001 in expression differences were evaluated further in principal component analysis
and genes with p0.0001 were evaluated further in gene set enrichment analysis. A total of
377 patients with gene expression data in 20,532 genes were included in the final analysis.
The numbers of patients in stage I through IV were 59, 147, 116 and 55, respectively. NEK4
gene, which encodes for NIMA related kinase 4, was differentially expressed across the four
stages of CRC. The stage I patients had the highest expression of NEK4 genes, while the
stage IV patients had the lowest expressions (p = 9*10−6). Ten other genes (RNF34,
HIST3H2BB, NUDT6, LRCh4, GLB1L, HIST2H4A, TMEM79, AMIGO2, C20orf135 and
SPSB3) had p value of 0.0001 in the differential expression analysis. Principal component
analysis indicated that the patients from the 4 clinical stages do not appear to have distinct
gene expression pattern. Network-based and pathway-based gene set enrichment analyses
showed that these 11 genes map to multiple pathways such as meiotic synapsis and pack-
aging of telomere ends, etc. Ten of these 11 genes were linked to Gene Ontology terms
such as nucleosome, DNA packaging complex and protein-DNA interactions. The protein
complex-based gene set analysis showed that four genes were involved in H2AX complex
II. This study identified a small number of genes that might be associated with clinical stages
of CRC. Our analysis was not able to find a molecular basis for the current clinical staging
for CRC based on the gene expression patterns.
Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of can-
cer-related deaths in the United States [1]. Among the five subtypes of CRC (adenocarcinomas,
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carcinoid tumors, gastrointestinal stromal tumors, lymphomas and sarcomas), adenocarcino-
mas are the most common (95% of all CRCs). Currently the staging of CRC, referred to as clini-
cal staging, is based on results of physical exams, biopsies, and imaging tests (CT or MRI scan,
X-rays, PET scan, etc.). The criteria of staging are based on: 1) how far the cancer has grown
into the wall of the intestine; 2) whether it has reached nearby structures; and 3) whether it has
spread to the nearby lymph nodes or to distant organs. The results of surgery can be combined
with clinical staging to determine the pathologic stages. The most often used CRC staging sys-
tem is the AJCC cancer staging manual developed by American Joint Committee on Cancer
(AJCC), based on conditions of primary tumor (T), regional lymph nodes (N) and distant
metastasis (M) [2]. The earliest stage cancers are called stage 0, then range from stage I through
IV, with additional sub-stages identified with the letters A, B and C [3].
Several genes, such as WNT, WAPK/PI3K, TGF-β, TP, have been associated with CRC. For
instance, mutations in adenomatous polyposis col (APC) gene, a tumor suppressor gene, were
found to be responsible for familial adenomatous polyposis and then further developed to
CRC [4]. MisMatch Repair system genes such as MLH1 and MSH2 gene were found to be asso-
ciated with Lynch syndrome, the most frequent form of hereditary CRC [5, 6]. Further, a
12-gene recurrence score assay has been developed as a prognostic factor in stage II-III colon
or rectal carcinoma [7–9]. Even though many genes have been associated with an increased
risk of CRC, the genetic differences across different stages of CRC have not been clearly identi-
fied. So far, only one study had assessed the gene expression levels of three candidate genes
(MMP9, MMP28 and TIMP1) across CRC stages and found no statistically significant differ-
ences based on the stage of CRC [10]. There have been no studies in the literature comparing
the gene expression levels in the entire transcriptome across CRC stages. The purpose of this
study is to explore transcriptome-wide gene expression differences across different stages of
CRC followed by gene ontology, gene set network analysis approaches based on the publicly
available RNAseq dataset in The Cancer Genome Atlas (TCGA) [11].
Materials and methods
Data acquisition
The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) is a joint effort between
the National Cancer Institute (NCI) and the National Human Genome Research Institute
(NHGRI) to facilitate the sharing of data and speed up cancer research [11, 12]. The Eli and
Edythe L. Broad (Broad) Institute of MIT and Harvard is a joint venture between both institu-
tions and several area hospitals (https://www.broadinstitute.org/about-us). Their “FireHose”
project ingests, aggregates, standardizes, and processes TCGA data via automated pipelines in
an attempt to accelerate analysis and discoveries (https://confluence.broadinstitute.org/
display/GDAC/Rationale).
The Broad Institute has established pipelines for processing each TCGA dataset and the
outputs from each stage of the pipeline are made available as a versioned set. Illumina HiSeq
expression data was processed by Broad Institute to output both reads per kilobase per million
mapped reads (RPKM) expression values [13] and RNA-seq by Expectation-Maximization
(RSEM) values [14] normalized to “upper quartile count at 1000”. TCGA clinical data and
expression data were manually downloaded from the Broad Institute (TCGA data version
2016_01_28) via the firebrowse.org website.
(http://firebrowse.org/?cohort=COADREAD&download_dialog=true). The code used to
download the data can be accessed here: https://github.com/indera/crc_transcriptome_
analysis.
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Data merging
Using Python 2.7.10 and version 0.19.0 of the Pandas module, the expression data from the
Broad Institute was read into a Pandas dataframe, transposed, and re-saved. The clinical data
were also transposed in the same manner. Additionally, in order to cut down on the size of the
data and number of components of interest, only a subset of the columns from the clinical
data were kept for the analysis. These included common demographic data such as patient
gender, race, ethnicity, and age; clinical data such as cancer stage, associated International
Classification of Diseases (ICD) 10 codes, presence of polyps, whether analysis had been done
for common mutations such as KRAS and BRAF; and finally, approximately 85 different ali-
quot identifiers from the TCGA dataset itself.
Matching of clinical data with expression data was performed using TCGA’s "hybridization
REF" identifier from the expression data and searching against the aliquot identifiers present
in the clinical data. Eventually, 377 patients with gene expression data from 20,532 genes were
included in the final analysis.
Differential expression analysis
Gene expression differences were evaluated across the disease stages using linear regression.
The standard deviation of the gene expression level for each gene was computed. The genes
with standard deviation of zero, which indicates no change in the gene expression, were
removed from further analysis. To select top genes that are differentially expressed across can-
cer stages, a linear regression model was performed for each gene to test the trend in gene
expression with increasing cancer stages. The analyses adjusted for age, gender and race/eth-
nicity of the patients. Genes with p0.0001 were considered suggestive and the expression
level by cancer stages were presented for these genes. Analyses were performed using R version
3.3.1 and SAS 9.4 (Cary, NC).
Principal component analysis
In order to identify gene expression pattern of the selected CRC samples across different
stages, all the genes with p0.001 in the linear model analysis were included in the principal
component analysis using SAS. Ten principal components (PCs) were identified and the first
two PCs were plotted according to the staging status of the CRC patients.
Gene annotation and gene set enrichment analysis
Genes with expression difference of p 0.0001 were evaluated further in gene annotation
using DAVID [15]. Then the gene IDs and official gene names were used for further analysis.
ConsensusPathDB tool [16, 17] was then used to perform network-based and pathway-based
analyses on these top genes. ConsensusPathDB consists of a comprehensive collection of
human, mouse and yeast molecular interaction data integrated from 32 different public reposi-
tories and a web interface with a set of computational methods and visualization tools to
explore these data (http://consensuspathdb.org). This tool applies computational methods for
statistical over-representation and enrichment analysis and reports network modules, path-
ways and functional information that are significantly enriched by any given gene list. Consen-
susPathDB provides 4 types of predefined annotation gene sets: neighborhood-based entity
sets (NESTs) which includes protein-protein interactions, biochemical interactions, gene regu-
latory and genetic interactions, protein complexes, pathways (including metabolic, signaling
and gene regulatory pathways) and GO terms [16]. For computing the significance of the
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enrichment of the annotation sets with respect to user-input gene list, this tool applies Wilcox-
on’s matched-pairs signed-rank test.
Results
Demographics
The TCGA database contains clinical information for 629 patients but only 396 unique
patients have both gene expression data and clinical data. The numbers of patients with CRC
in stage I through IV were 59, 147, 116 and 55 respectively and 19 patients did not have stage
information and there were no patients in the stage 0. The mean age of these patients was
64 ± 12 years. Further, 46.4% were women, 69.2% were white, 16.2% were Black/African
American, 14.6% were Asian, American Indian/Alaska Native and of unspecified race, and
1.1% were Hispanics. From a clinical standpoint, 76.7% had colon cancer and 23.3% had rectal
cancer. The demographic and relevant clinical information of these patients stratified by CRC
stage are summarized in Table 1. The final analysis included 377 patients with clinical data
including staging information and gene expression in 20,532 genes.
Linear model for gene expression
Eleven genes had p0.0001 in the differential gene expression analysis according to the clini-
cal staging. NEK4 gene, which encodes for NIMA related kinase 4, was differentially expressed
across the four stages of CRC. The samples from the stage I patients had the highest expression
Table 1. Demographics of patients by CRC cancer stages.











Age Mean, SD 65 ± 12 67 ± 12 63 ± 13 60 ± 13 64 ± 13
Height Mean, SD (cm) 172 ± 10.8 166.9 ± 12.8 169.0 ± 10.8 171.8 ± 10.9 169.1 ± 11.8
Weight (Kg) 83.1 ± 19.7 77.8 ± 23.3 81.4 ± 20.1 80.6 ± 17.7 80.3 ± 21.2
BMI 28.1 28.0 28.5 27.3 28.1
Sex
Female 25 72 54 24 175 (46.4%)
Male 34 75 62 31 202 (53.6%)
Vital Status
Alive 57 133 103 39 332 (88.1%)
Dead 2 14 13 16 45 (11.9%)
Race
White 43 93 86 39 261 (69.2%)
Black/African American 8 20 22 11 61 (16.2%)
Other 8 34 8 5 55 (14.6%)
Ethnicity
Hispanic or Latino 0 1 1 2 4 (1.1%)
Not Hispanic or Latino 49 121 105 47 322 (85.4%)
Other 10 25 10 6 51 (13.5%)
Cancer Type
Colon 46 119 83 41 289 (76.7%)
Rectal 13 28 33 14 88 (23.3%)
SD: standard deviation. Continuous variables were summarized as mean and SD and categorical variables were summarized as number (%).
https://doi.org/10.1371/journal.pone.0188697.t001
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of NEK4 genes, while the stage IV had the lowest expressions (p = 4.5010−6) (Table 2, Fig 1).
Ten other genes had p value of 0.0001 in the unadjusted differential expression analysis includ-
ing two with decreasing gene expression levels in more advanced CRC stages (RNF34 and
NUDT6) and eight with increasing gene expression levels in more advanced CRC stages (LRCH4,
HIST3H2BB, SPSB3, HIST2H4A, TMEM79, AMIGO2, GLB1L and C20orf135) (Table 2, Fig 1).
Principal component analysis
Principal component analysis result indicated that the first principal component (PC1)
explained 16% of the variability, while PC2 explained 9.7% and PC3 explained 4.8% of the vari-
ability in the gene expression data in all the CRC samples. Fig 2 illustrated PC1 vs. PC2 for all
the CRC samples across four stages. The samples from these four stages do not appear to have
distinct gene expression patterns.
Gene annotation and network-based analysis
Network analysis showed that the top eleven genes map to multiple pathways such as meiotic
synapsis and packaging of telomere ends, etc. (S1 Table). Ten of these 11 genes were linked to
Gene Ontology (GO) terms such as nucleosome, DNA packaging complex and protein-DNA
interactions (S2 Table). The protein complex-based gene set analysis showed that four genes
were involved in H2AX complex II with q value of 5.7210–5 (S3 Table). The enriched neigh-
borhood based sets analysis of these 11 genes (S1 Fig) identified CDC like kinase 2 be con-
nected with most genes (386 genes) in the neighborhood. RNF4 and RNF8 genes, in the same
family as one of the top genes (RNF34), were also well-connected with multiple genes in path-
ways. Finally, the induced network module analysis identified several genes with gene protein
interaction: HIST2H4A, HIST3H2BB, LRCH4 and NUDT6 (S2 Fig).
Discussion
Using publically available data from TCGA, this study explored the gene expression differ-
ences across four stages of CRC. We found that eleven genes showed suggestive level of evi-
dence for differential expression in a linear fashion. These genes map to multiple pathways
and were linked to GO terms. Further, several few genes were enriched in protein complexes.
However, a principal component analysis was not able to identify a molecular basis for the cur-
rent CRC staging process. This might be due to the following: 1) due to the limitation of publi-
cally available data, our study was not able to compare the gene expression data from different
Table 2. The top genes in the linear regression analysis.
Gene Gene ID Gene Full Name P (unadjusted) P (adjusted)
NEK4 6787 NIMA related kinase 4 9.00E-06 4.50E-06
LRCH4 4034 leucine rich repeats and calponin homology domain containing 4 1.00E-04 2.40E-05
HIST3H2BB 128312 histone cluster 3 H2B family member b 1.00E-04 8.90E-05
SPSB3 90864 splA/ryanodine receptor domain and SOCS box containing 3 1.00E-04 1.33E-04
HIST2H4A 8370 histone cluster 2 H4 family member a 1.00E-04 1.50E-04
TMEM79 84283 transmembrane protein 79 1.00E-04 1.71E0-4
AMIGO2 347902 adhesion molecule with Ig like domain 2 1.00E-04 1.71E0-4
GLB1L 79411 galactosidase beta 1 like 1.00E-04 2.00E-04
RNF34 80196 ring finger protein 34 1.00E-04 2.23E-04
C20orf135 140701 1.00E-04 2.40E-04
NUDT6 11162 nudix hydrolase 6 1.00E-04 3.10E-04
https://doi.org/10.1371/journal.pone.0188697.t002
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Fig 1. Top gene expression levels by CRC cancer stage.
https://doi.org/10.1371/journal.pone.0188697.g001
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CRC stages with a normal control; 2) the CRC staging system currently uses the size of lesion
for staging, not molecular basis; and 3) the principal component analysis was able to cover
only ~30% of the variance in the gene expression data. Such analysis has not been done previ-
ously in the literature.
Fig 2. Principal component 1 and principle component 2 by cancer stage.
https://doi.org/10.1371/journal.pone.0188697.g002
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Among the genes with suggestive level of significance, only a few had possible link with can-
cer in the literature. The gene with the strongest p value for differential expression by stage is
NEK4 gene, which encodes NIMA related kinase 4, a serine/threonine protein kinase required
for normal entry info replicative senescence. In cell culture, suppression of NEK4 doubled the
number of replications needed to reach senescence, reduced cellular reactions to double-
stranded DNA damage in both recruitment of repair proteins and arresting of further cell divi-
sions, and also reduced activity of the p53 tumor suppressor protein [18]. Our study suggested
that the CRC patients in the higher stages have lower NEK4 gene expression compared to
lower stages, this is consistent with the direction shown in tissue culture [18] that lower expres-
sion was associated with worse diagnosis.
RNF34 gene, which encodes ring finger protein 34, was first known and characterized as
hRFI (human ring finger homologous to inhibitor of apoptosis protein type) in 2005, was
shown to have anti-apoptotic properties [19], and later was shown to also play a role in regula-
tion of p53 via ubiquitination and subsequent proteasomal degradation [20]. Overexpression
of this gene was shown to confer the resistance to 5-fluorouracil-induced apoptosis in colorec-
tal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL [21]. In
our study, RNF34 had lower expression in those in the more advanced clinical stages of CRC
patients. This seems indicate that more advanced CRC patients may be more sensitive to
5-fluorouacil treatment compared to patients in earlier stages, but this is outside the scope of
our study. However, it is worth noting that 5-fluorouacil is currently recommended as one of
the adjuvant chemotherapy agents for stage III and high-risk stage II colon cancer patients
[22].
HIST3H2BB and HIST2H4A, both encoding histone proteins, were also among the top dif-
ferentially expressed genes, increasing in expression with increasing cancer stages. Eukaryotic
DNA that is not currently being replicated is stored in a wrapped and coiled form around four
pairs of histone proteins that provide support for the coiled DNA. Histones are also sensitive
to post-translational modification, such as acetylation and deacetylation, which the cells use to
help regulate transcription [23]. A direct link to the role of increased histone protein expres-
sion isn’t clear, perhaps further examination of co-expression levels of histone acetyltrans-
ferases and deacetylases would suggest a link.
Members of the NUDT6 gene family exhibit behaviors that include controlling the level of
cellular metabolites and signaling compounds as well as degrading “potentially mutagenic”
oxidized nucleotides” [24]. The trend of downregulation of this gene across cancers stages
would indeed contribute to the ability of cancer cells to continue to grow, divide, and evade
normal cellular precautions.
LRCH4 gene encodes leucine rich repeats and calponin homology domain containing 4,
which is a protein that contains leucine-rich repeats at its amino terminus and that is known
to be involved in ligand binding. AMIGO2, which encodes adhesion molecule with Ig like
domain 1, is a leucine-rich repeat family member. AMIGO2 mRNA was found to be differen-
tially expressed in near half of cancer vs. normal tissue from gastric adenocarcinoma patients
[25]. In an antisense study, it was found that the inhibition of AMIGO2 expression negatively
impact tumor growth and altered chromosomal stability [25].
Our study has some limitations: 1). TCGA CRC data only included data on samples from
cancer patients, therefore the only analysis we could perform was within cancer samples and
using controls from a different source would bring too much confounding. 2) The data from
TCGA had many field with missing information, such as medication information, which may
be altering gene expression in some of the genes or loci of interest. Therefore, no meaningful
analysis can be performed with the medication data.
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In conclusion, our study identified several genes that might be associated with clinical
stages of CRC. Our analysis also suggests that the current clinical staging might not have
molecular basis according to the gene expression patterns.
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